FDA approves DVT prevention device

California-based ManaMed has launched the U.S. Food and Drug Administration (FDA) approved deep vein thrombosis (DVT) prevention device PlasmaFlow in the United States.

The portable, tubeless and digital PlasmaFlow, which comes with multiple pressure functions, helps to prevent the onset of DVT in patients by revitalizing blood flow in the extremities.

ManaMed co-founder and CEO Trevor Theriot said that the easy-to-operate sequential compression system can be used at home or hospital to help mitigate the risk to 600,000-plus new cases of DVT every year in the United States. “Blood Clots are a silent killer in the medical industry and we decided to up the fight against DVT related deaths,”

Theriot said. PlasmaFlow can also be used to improve blood circulation, manage post-operative pain and swelling and help in faster wound healing time.

The sequential compression device can also help in treating stasis dermatitis, arterial and diabetic leg ulcers, chronic venous insufficiency, venous stasis ulcers, and edema in the lower limbs.

Additionally, PlasmaFlow finds it use as an aid in the prophylaxis for DVT by people who do not move around much for long durations.

Theriot said that the device incorporates step-up-technology while featuring a one-button operation and soft cuffs made of high-grade medical material.

PlasmaFlow comes with a rechargeable battery that can sustain itself for up to 10 hours on one charge. It also has a couple of LCD screens to track usage and pressure.